Monitoring of Circulating Tumor DNA Predicts the Response and Prognosis of Initially Unresectable Metastatic Colorectal Cancer with VEGFR-TKI Maintenance Therapy

ABSTRACT: Interventions: Group of VEGFR-TKI maintenance therapy:None;Group of standard maintenance treatment group:None Primary outcome(s): 6-Months Progression-free survival Study Design: Cohort study

DISEASE(S): Colorectal Cancer

PROVIDER: 83521 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR